MTFEM
MTFEM, also known as 4--2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The drug is also the α-methyl or amphetamine analogue of 2C-O-22.In humans, MTFEM produced stimulant effects at a dose of 2.5mg and had a duration of 12hours. Its full effects in humans were not determined and it was estimated that its human dose range would be 10mg or more. Along with TMA-2 and MEM, it is one of the few compounds in its series tested and known to be active in humans.Pharmacology
Pharmacodynamics
MTFEM acts as a potent modulator of the serotonin 5-HT2 receptors. Its affinities were 460nM for the serotonin 5-HT2A receptor and 2,400nM for the serotonin 5-HT2C receptor, whereas its activational potencies ) were 19nM at the serotonin 5-HT2A receptor and 200nM at the serotonin 5-HT2B receptor. Hence, MTFEM is a near-full agonist of the serotonin 5-HT2A receptor but a near-silent antagonist of the serotonin 5-HT2B receptor. Besides the serotonin 5-HT2 receptors, the drug showed little to no activity at various other assessed targets, such as the monoamine transporters. It does not appear to have been tested for psychedelic-like activity in animals.History
MTFEM was first described in the scientific literature by Daniel Trachsel in 2012. Its psychoactive effects in humans were reported by Trachsel and colleagues in 2013. Subsequently, it was characterized in more detail by a group including Trachsel and Matthias Liechti in 2019. The compound's name is said to derive from its benzene ring substituents, "methoxy trifluoroethoxy methoxy".Society and culture
MTFEM is a controlled substance in Canada under phenethylamine blanket-ban language.